Anzeige
Mehr »
Donnerstag, 11.09.2025 - Börsentäglich über 12.000 News
BREAKING NEWS: CiTech unterzeichnet Exklusivvertrag mit Babcock - Ukraine-Deal katapultiert Aktie in neue Liga
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N87T | ISIN: SE0007413455 | Ticker-Symbol: 78D
Frankfurt
10.09.25 | 16:43
0,097 Euro
+2,97 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALZINOVA AB Chart 1 Jahr
5-Tage-Chart
ALZINOVA AB 5-Tage-Chart

Aktuelle News zur ALZINOVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.09.Alzinova AB: Alzinova Receives FDA (IND) Approval for Phase II Study of ALZ-101 in Alzheimer's Disease71Alzinova AB (publ) (Nasdaq First North: ALZ) today announces that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for its planned Phase...
► Artikel lesen
28.08.Alzinova - Innovative new approach to Alzheimer's264Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments for Alzheimer's disease (AD) via protein modification and immunotherapy-based solutions. Alzinova's...
► Artikel lesen
21.08.Alzinova AB Q2 Sales Increase-
21.08.Alzinova AB: Alzinova publishes half-year January - June 202595The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the half-year report for the period January - June 2025. The full report, which is attached in the press release...
► Artikel lesen
11.08.Alzinova AB: Alzinova submits applications for clinical trial initiation (IND) and Fast Track status to the FDA239Alzinova AB (publ) (Nasdaq First North: ALZ) today announced that the company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for the planned...
► Artikel lesen
ALZINOVA Aktie jetzt für 0€ handeln
19.06.Alzinova AB: Alzinova's ALZ-101 vaccine shows new promising results in normalizing protective antibody levels in Alzheimer's disease patients169Alzinova AB (ALZ) announces new clinical results showing that healthy elderly people naturally have high levels of protective antibodies against toxic amyloid-ß oligomers, which are reduced in Alzheimer's...
► Artikel lesen
17.06.Alzinova AB: Alzinova selects Worldwide Clinical Trials as CRO partner for Phase 2 study of ALZ-101410Alzinova AB (Nasdaq First North: ALZ) today announces a strategic collaboration with Worldwide Clinical Trials ("Worldwide"), a global leader in neuroscience studies, appointing them as the Clinical...
► Artikel lesen
28.05.Alzinova AB: Bulletin from the Annual General Meeting of Alzinova AB (publ)173Alzinova AB (publ) (the "Company") held its Annual General Meeting ("AGM") in Gothenburg on 28 May 2025. The following resolutions were passed at the meeting. Adoption of the annual accounts and discharge...
► Artikel lesen
15.05.Alzinova AB: Alzinova publishes interim report January - March 2025139The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2025. The full report, which is attached in the press release,...
► Artikel lesen
24.04.Alzinova AB: Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial226Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer's disease. This...
► Artikel lesen
11.04.XFRA CAPITAL ADJUSTMENT INFORMATION - 11.04.2025437Das Instrument J1X BMG4660A1036 HIMALAYA SHIPPING LTD DL1 EQUITY wird cum Kapitalmassnahme gehandelt am 11.04.2025 und ex Kapitalmassnahme am 14.04.2025 The instrument J1X BMG4660A1036 HIMALAYA SHIPPING...
► Artikel lesen
02.04.Alzinova AB: The Board of Directors of Alzinova resolves on a rights issue of shares of approximately SEK 35.7 million169NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, CANADA, THE UNITED...
► Artikel lesen
27.03.Alzinova AB: Final results confirm positive phase 1b results with ALZ-101 against Alzheimer's disease419Alzinova AB (publ) (ticker: ALZ) today announces that the final analysis of data from the Phase 1b clinical study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's disease...
► Artikel lesen
07.03.Alzinova AB: Bulletin from the Extraordinary General Meeting of Alzinova AB (publ)180The following resolution were passed at the extraordinary general meeting (the "EGM") of Alzinova AB (publ) ("the Company") on 7 March 2025 in Gothenburg. Long-term incentive program (LTIP 2025:1 for...
► Artikel lesen
27.02.Alzinova AB: Alzinova publishes year-end report 2024239The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year-end report for the period January - December, and the fourth quarter, 2024. The full report, which is attached...
► Artikel lesen
03.02.Alzinova AB: All study participants have completed the final visit in the Phase 1 study252Alzinova AB (publ) (ticker: ALZ) announces that another milestone in the development of the company's vaccine candidate ALZ-101 for Alzheimer's disease has been reached. All study participants have...
► Artikel lesen
28.01.Alzinova AB: Alzinova strategically realigns CMO position to enhance collaboration and drive next development phase368Alzinova AB (publ) (ticker: ALZ) hereby announces that the Company's CMO is stepping down from her role after mutual agreement. The basis is a strategic decision to appoint a CMO in place at the Company's...
► Artikel lesen
09.12.24Alzinova AB: Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease309ALZ-101 continues to demonstrate a favorable safety and tolerability profile after at least 84 weeks of study inclusion.The immune response from vaccination with ALZ-101 is robust and long-lasting in...
► Artikel lesen
14.11.24Alzinova AB: Alzinova publishes interim report January - September 2024256The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1